Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis by Granziera, Cristina et al.
REVIEW ARTICLE
Quantitative magnetic resonance imaging
towards clinical application in multiple sclerosis
Cristina Granziera,1,2 Jens Wuerfel,3,4 Frederik Barkhof,5,6 Massimiliano Calabrese,7
Nicola De Stefano,8 Christian Enzinger,9 Nikos Evangelou,10 Massimo Filippi,11,12
Jeroen J.G. Geurts,13 Daniel S. Reich,14 Maria A. Rocca,11 Stefan Ropele,15
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Quantitative MRI provides biophysical measures of the microstructural integrity of the CNS, which can be compared across CNS
regions, patients, and centres. In patients with multiple sclerosis, quantitative MRI techniques such as relaxometry, myelin imaging,
magnetization transfer, diffusion MRI, quantitative susceptibility mapping, and perfusion MRI, complement conventional MRI
techniques by providing insight into disease mechanisms. These include: (i) presence and extent of diffuse damage in CNS tissue
outside lesions (normal-appearing tissue); (ii) heterogeneity of damage and repair in focal lesions; and (iii) specific damage to CNS
tissue components. This review summarizes recent technical advances in quantitative MRI, existing pathological validation of
quantitative MRI techniques, and emerging applications of quantitative MRI to patients with multiple sclerosis in both research
and clinical settings. The current level of clinical maturity of each quantitative MRI technique, especially regarding its integration
into clinical routine, is discussed. We aim to provide a better understanding of how quantitative MRI may help clinical practice by
improving stratification of patients with multiple sclerosis, and assessment of disease progression, and evaluation of treatment
response.
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Introduction
Conventional MRI provides invaluable information for the
diagnosis, prognosis, and monitoring of the effectiveness of
therapeutics in patients with multiple sclerosis.1,2 The term
conventional MRI encompasses the methods used in clinical
practice to describe pathology by relying on contrast changes
in weighted images. These are images that predominantly, but
not exclusively, reflect a biophysical contrast mechanism (e.g.
T1- and T2-weighted scans). Using conventional MRI in the
multiple sclerosis clinic, it is generally possible to identify the
number, location, and activity of multiple sclerosis lesions, al-
though the sensitivity to those characteristics generally varies
depending on several technical factors.3 On the other end,
conventional MRI is largely insensitive to the heterogeneity of
focal multiple sclerosis lesions and to the pathology affecting
CNS tissue outside multiple sclerosis lesions (normal-appear-
ing white and grey matter). Furthermore, conventional MRI
is unable to depict the level of damage within different CNS
tissue components, such as myelin, axons, and glia.
Better quantification of the extent, type, spatial distribu-
tion, and evolution over time of CNS tissue damage in
patients with multiple sclerosis could improve our under-
standing of disease mechanisms. It may also aid in stratifica-
tion of disease burden, assessment of therapy response and
evaluation of subclinical disease progression.
Quantitative MRI can potentially address these needs by
providing more sensitive measures of multiple sclerosis path-
ology and more specific information regarding which tissue
component has been damaged (Fig. 1). Unlike conventional
MRI, which acquires datasets that have a mixture of weight-
ings and therefore cannot be resolved into a quantitative
map, quantitative MRI relies exclusively on acquisitions that
can then be used to disentangle the source of signal varia-
tions. Moreover, through computational or mathematical
modeling, this approach can provide quantitative maps
where intensities have physical units.4 Thus, quantitative
MRI techniques are superior to conventional MRI regarding
their sensitivity to subtle alterations within lesions and nor-
mal-appearing tissue4 as well as their increased specificity
relating to the damage of different tissue components of the
CNS (e.g. myelin, axons, glia, iron and blood flow/volume).
Nonetheless, quantitative MRI is not currently used in clin-
ical practice, primarily because it has not reached ‘clinical ma-
turity’. A method can be considered ‘clinically mature’ when it
can be run on most up-to-date clinical scanners without the
need for additional sequence development, there is available
and validated software able to process the data and provide
the user with the desired quantitative maps, and cut-off values
of pathology assessed with that method have been established.
In this review, we summarize: (i) the information that can,
and cannot, be provided by conventional MRI; (ii) the con-
tribution of quantitative MRI to our understanding of mul-
tiple sclerosis pathology in the brain and spinal cord; (iii) the
relationship between quantitative MRI features and clinical
outcome and the potential role of quantitative MRI in
improving the prediction of disability, especially motor and
cognitive deficits; and (iv) the clinical maturation stage of




When radiographically investigating multiple sclerosis, con-
ventional MRI provides the following measures: (i) number,
volume, and location of focal T2-weighted hyperintense
lesions; (ii) number of contrast-enhancing T1-weighted
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lesions (CEL); (iii) number and volume of T1-hypointense
lesions (also called black holes); and (iv) global/regional vol-
ume of tissues (a measure of atrophy). However, T2-
weighted lesions are not pathologically specific, because they
may represent active inflammation (e.g. oedema) as well as
demyelination with or without axonal loss. T1-hypointense
lesions may also result from variable damage to different
CNS tissue components (myelin/axon/cells), which cannot be
distinguished. Therefore, T2-weighted and T1-hypointense
lesions provide only basic information relating to the histo-
pathological heterogeneity of multiple sclerosis lesions5,6 and
the different stages of lesion development and repair (e.g.
remyelination) that may occur over time. Additionally, brain
atrophy reflects only the late-stage results of degenerative
phenomena and does not describe the normal-appearing tis-
sue pathology preceding tissue volume loss. In fact, conven-
tional MRI is mostly insensitive to the early and subtle
axonal pathology,7 alterations in myelin morphology (e.g.
myelin blisters8) and early-stage dendrite/synapse changes
such as those occurring in the hippocampus.9
Quantitative MRI techniques
T1 relaxometry
T1 relaxometry measures the recovery of longitudinal mag-
netization of excited spins in a tissue by providing T1
relaxation time (T1-RT) values, which are related to the in-
tegrity of micro- and macrostructural components of a tis-
sue10 (Table 1).
Pathological evidence
Several studies have explored the sensitivity and specificity of
T1-RT for detecting multiple sclerosis pathology (Table 1).
The three major determinants of T1 changes in the CNS of
patients with multiple sclerosis are myelin, iron, and water.
While it is possible to model their effect on T1-RT,
11 it is chal-
lenging to disentangle the relative contributions of myelin,
axons, and free water (e.g. oedema in active lesions) to T1-
RT.12 Indeed, T1-RT highly correlates with both myelin (r =
–0.78, P50.001) and axon content (r = –0.62, P50.001)
within the normal-appearing white matter and within white
matter lesions in the CNS.13 Moreover, demyelination, axon
loss, and iron loss may all lead to prolonged relaxation
times.13,14 Interestingly, lesions with longer T1-RT are more
destructive due to a combination of axonal loss and accumu-
lation of extracellular water.15 On the other hand, shortening
or moderate prolongation of T1-RT over time may suggest
reparative phenomena such as remyelination and gliosis.16
Assessment of multiple sclerosis impact and
prognostic value
T1-RT mapping displays high accuracy for discriminating
focal lesions in both white and cortical grey matter in
Figure 1 Information provided by quantitative MRI about key features of multiple sclerosis pathology for clinical applications
in patients with multiple sclerosis. Quantitative MRI provides information about normal-appearing tissue pathology, multiple sclerosis lesion
heterogeneity, remyelination, and blood–brain barrier disruption. dia-mag = diamagnetic; para-mag = paramagnetic.








niversity of Verona user on 11 M
ay 2021
patients with multiple sclerosis.17,18 Ultra-high-field (7 T),
T1-RT mapping can identify cortical focal pathology in cere-
bral hemispheres19 and cerebellum20 of patients with mul-
tiple sclerosis. In addition, whole-brain T1-RT maps at 3 T
provide a personalized approach with which to assess the
heterogeneity of damage in focal lesions and the extent of
diffuse pathology by quantifying the changes in T1-RT com-
pared to the normal distribution of T1-RT in healthy sub-
jects.21 T1-RT mapping studies have been used to generate
whole-brain assessments of multiple sclerosis disease impact
and progression. These studies found that global T1-RT
increases with disease progression, predominantly in later
disease stages and also correlates with brain atrophy.22,23
The volume of lesions with very long T1-RT (black holes)
better correlates with composite clinical functional scores
compared with total lesion volume,24 and the decrease over-
time in T1-RT inside black holes is associated with clinical
improvement25 and response to therapy.25 Finally, patterns
of T1-RT change associated with cognitive impairment can
be observed even at early multiple sclerosis stages.26
Technology availability in the clinic
To date, T1 relaxometry has not been included in clinical
multiple sclerosis protocols. There are several reasons for
this: (i) numerous approaches have been proposed, exhibit-
ing variable sensitivity to spurious effects such as magnetiza-
tion transfer (MT), T2 relaxation, diffusion, and B1
variation; (ii) there is no consensus for the best T1 mapping
sequence27,28; (iii) obtaining high accuracy for T1 mapping
in vivo is still challenging29 (e.g. T1 relaxation in white
Table 1 Technical background and pathological specificity and sensitivity of quantitative MRI techniques
Quantitative MRI
technique








High: (lesions and NAT)
T2 relaxometry Loss of spin
Coherence of water pools (myelin
layers, intracellular, intra-axonal,
extracellular)
T2-RT/R2 Low: myelin/axons/cells/water) High: (lesions and NAT)
MWI Loss of spin coherence of water
molecules trapped in myelin
MWF High: myelin High: (lesions and NAT)
MTI Exchange of magnetization be-




(e.g. lipid/protein in biological
membranes) extracellular
water
High: (lesions and NAT)
DTI Diffusivity of water proteins (intra-
cellular-extracellular)
MD, RD/AD, FA Low
Highly dependent on tissue
structure (e.g. fibre crossing/
activated microglia/cells)




Modelling of water compartments












NDI: myelin and axonal count
fis: Neurite and soma
High: (lesions and NAT,
little evidence)
QSM Local changes in tissue composition
cause frequency shifts (measured
by phase images)












Moderate: linked to mitochon-
drial energetic failure; linked
to elevated levels of endothe-
lin-1
Moderate: (NAT)
DSC Susceptibility effect of the para-
magnetic contrast agent leads
to signal loss in T2/T2*-
weighted images
DCE Wash-in, plateau, wash-out of
contrast enhancement
The evaluation of ‘specificity’ and ‘sensitivity’ of quantitative MRI measures has been made along two criteria: (i) the strength of correlation between quantitative MRI measures with
a given neuropathological feature (specificity); and (ii) the number of neuropathological features measured with quantitative MRI (sensitivity). Based on those criteria, an expert con-
sensus was reached a consensus among the participants of the MAGNIMS workshop (Basel, December 2019) on ‘Quantitative MRI towards clinical application in MS’. ASL = arterial
spin labelling; CBF = cerebral blood flow; CBV = cerebral blood volume; DCE = dynamic contrast-enhanced; DSC = dynamic susceptibility contrast; fis = soma signal fraction;
GM = grey matter; GRASE = gradient and spin echo; ICVF = intracellular volume fraction; Ktrans = transfer constant; MTI = magnetization transfer imaging; MTT = mean transit
time; MWI = myelin water imaging; NDI = neurite density index; ODI = orientation dispersion index; Ve = fractional volume of the extracellular space; Vp = fractional volume of
the plasma space.
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matter is double-exponential because of magnetization ex-
change with myelin-bound protons, but most available
methods assume single-exponential relaxation); and (iv) the
complexity of the T1 mapping techniques often results in
lack of reproducibility30 (Table 2).
Despite challenges with reproducibility of T1 relaxometry,
there are some promising T1 mapping approaches combin-
ing ‘clinically compatible’ scan times with high intra- and
inter-scanner reproducibility. One of these is the magnetiza-
tion prepared 2 rapid acquisition gradient echoes
(MP2RAGE) sequence,31 which has been shown to provide
highly reproducible T1-RT maps (3% coefficient of variabil-
ity, CV) in a single-vendor, multicentric study32 and in a T1
phantom study (NIST, National Institute of Standards and
Technology) across different 3 T scanners.33 MP2RAGE T1
maps provide a promising ‘all-in-one’ candidate for clinical
practice, but achieving this will require manufacturers to col-
laborate to provide similar acquisitions across different scan-
ners. In addition, clinical cut-offs of pathological changes in
MP2RAGE maps still need to be defined. Another interest-
ing approach is synthetic MRI (SyMRIV
R
), which simultan-
eously analyses T1/T2 relaxometry and proton density.
34
The SyMRI sequence and the software to reconstruct
SyMRI maps can be implemented across scanners from all
major vendors. Further, quantitative MRI maps can either
be generated within a minute of the acquisition or can be
installed as a call button on picture archiving and communi-
cation systems.35 Moreover, SyMRI showed less than 6%
variability in T1-RT across scanners from different
vendors.36
Interestingly, MP2RAGE T1 mapping has been recently
reported in the spinal cord in 5 10 min, with a maximum
CV of 5%.37
T2 relaxometry, myelin water
fraction, and magnetization transfer
imaging
Myelin-sensitive metrics are essential to investigate multiple
sclerosis pathophysiology38,39 (Fig. 1), perform outcome pre-
dictions,40,41 and assess therapeutic effects.42,43
Single-component T2 relaxometry (qT2) is obtained by fit-
ting a single exponential and provides measures of T2-RT
that are sensitive to global water content in the CNS (intra/
extracellular water and myelin water). Nevertheless, since T2
decay in the CNS tissue is largely multi-exponential, single-
component qT2 in highly dependent on sequence parameters
and noise44,45 (Table 1).
The distinction of different water pools, including the
myelin water pool [e.g. myelin water fraction (MWF)], in
the CNS may be achieved by using multi-component T2
relaxometry46 (Table 1). MT imaging exploits the selective
saturation of protons bound to macromolecules, including
myelin, and reduces their longitudinal magnetization. This
renders it possible to create MT saturation images (MTsat)
and magnetization transfer ratio (MTR) images providing
information about this pool of molecules13 (Table 1).
Single-component T2-RT, MWF, and MTR are also sensi-
tive to the relative presence of extracellular water. For ex-
ample, their values may be influenced by the presence of
oedema44,47 (Table 1).
Other techniques, such as rapid estimation of myelin for
diagnostic imaging (REMyDI), which is derived from
SynMRI, can also be used to assess myelin integrity.
REMyDI quantifies myelin by estimating its fast relaxation
rate through magnetization exchange and effects on the
observable proton pool (i.e. cellular water, free water, and
excess parenchymal water partial volumes).34,48
Pathological evidence
Myelin-related measures exhibit different specificity in re-
gard to myelin content and myelin-related pathology in mul-
tiple sclerosis.
Post-mortem single-component T2 relaxometry in the nor-
mal-appearing tissue of the cervical spinal cord of patients
with multiple sclerosis is highly influenced by demyelination
(r = 0.77, P5 0.001) but does not seem to be strongly
related to axonal damage (r = –0.44, P5 0.001).49
Additionally, qT2 shows a strong linear correlation with
iron concentration in healthy brains (r2 = 0.67,
P5 0.001).50
MWF shows strong correlations with myelin staining in
both lesions and normal-appearing tissue in histological
Table 2 Current state of reproducibility and availability for use in humans
Quantitative MRI technique Inter-scanner reproducibility Hardware/software




T2 relaxometry Moderate Limited
MWI High (little evidence) Limited
MTI Low/moderate Limited
DTI Moderate Broad
Models of diffusion-based microstructure Moderate (little evidence) Limited
QSM High (little evidence) Limited
Perfusion MRI (ASL, DSC, DCE) High Broad
Reproducibility (inter-scanner and same field strength): high = 55% coefficient of variation (CV); moderate = 5–15% CV; low = 4 15% CV in reported studies. ASL = arterial
spin labelling; DCE = dynamic contrast-enhanced; DSCE = dynamic susceptibility contrast; MTI = magnetization transfer imaging; qT1 = quantitative T1.
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specimens of human brain (on average in lesions and
normal-appearing tissue: r2 = 0.67, P5 0.0001).46,51
Whether MWF is also sensitive to accumulation of extracel-
lular iron remains to be demonstrated. A recent post-mortem
study attempted to answer this question by imaging brain
specimens with two different techniques measuring MWF
[Carr Purcell Meiboom Gill (CPMG), and gradient and spin
echo (GRASE)], before and after a de-ironing procedure.52
This work concluded that both were sensitive to brain iron
content; however, this conclusion should be taken with cau-
tion, since the applied de-ironing procedure may well have
affected the iron content within myelin and, as a conse-
quence, altered myelin properties. Therefore, more studies
are warranted to better understand the effect of extracellular
iron on quantitative MRI techniques measuring MWF.
MTR, but not MTsat, has been validated by post-mortem
studies and shows high correlations with myelin (r = 0.84,
P50.001)53 and axon density (r = 0.83, P5 0.0001)54
when lesions and normal-appearing tissue are considered to-
gether. In addition, very recent MRI-pathology studies dem-
onstrate that MTR sampled in lesion and non-lesion tissue
in multiple sclerosis brains is weakly associated not only
with myelin density [coefficient (95% confidence interval,
CI): 0.31 (0.07 to 0.55), P = 0.01], but also with greater
numbers of astrocytes [coefficient (95% CI): 0.51 (0.02
to 1), P = 0.04] and damaged mitochondria [coefficient
(95% CI): 0.53 (–0.95 to –0.12), P = 0.01].55
Amongst the most recent myelin-sensitive approaches,
REMyDI myelin quantification was shown to weakly cor-
relate with both proteolipid protein (PLP) immunostaining
and Luxol fast blue staining in multiple sclerosis lesions
but not with the same staining in normal-appearing white
matter (multiple sclerosis lesions: 0.025 r50.48,
P5 0.001).56
Assessment of multiple sclerosis impact and prognostic
value
In patients with short disease duration (i.e. 56 years),
T2-RT values were increased in normal-appearing white
matter57-59 and normal-appearing grey matter60 as
compared to healthy controls. T2-RT in combination with
diffusion MRI appeared to be sensitive also to extracellular
water accumulation due to blood–brain barrier disruption in
gadolinium-positive lesions, which could be identified
with 85% accuracy using these two measures.61 Similarly,
MWF increased over 6 months following the appearance of
enhancing lesions, as expected in repairing tissue.62
Additionally, MWF was reported to be lower in lesions with
paramagnetic rims compared with rim-negative lesions,63
showing the more pronounced demyelination in the former
lesion type. Also, MWF moderately decreased over time (–
8%) in the normal-appearing white matter of a small group
of patients followed over an average period of 5 years.
Global MWF was likewise abnormal in the brain and
cervical spinal cord of patients with primary progressive
multiple sclerosis compared to controls,64 and, when
followed for 2 years, decreased at the C2–C3 spinal cord
level65; moreover, cervical spinal cord MWF showed an as-
sociation with disability.65
MTR changes in normal-appearing white matter preceded
the appearance of gadolinium-enhancing lesions in patients
with multiple sclerosis66 and recovered following the acute
phase,67 especially in treated patients.68 MTR was signifi-
cantly lower in hypointense lesions as compared with isoin-
tense lesions on T1-weighted images at the time of initial
enhancement.69 For lesions that changed from hypointense
to isointense, MTR increased significantly during 6 months
of follow-up.69 Intralesional MTR showed longitudinal
changes consistent with demyelination and remyelination in
different regions of active lesions in the 3 years following
treatment.70 MTR also appeared to be lower in outer com-
pared to inner cortical layers in the brain, and in the subpial
region compared to the central region in the spinal cord71;
this may be consistent with differences in myelin content,
but may also, at least in part, be due to partial volume
effects. The lowest outer cortical MTR was seen in second-
ary progressive multiple sclerosis and is consistent with more
extensive outer cortical (including subpial) pathology.72
MTR abnormalities in the subpial region, in both brain and
spinal cord, occurred early in the course of multiple sclerosis
and were more marked in patients with a progressive disease
course.73 As for the spinal cord, lower MTR values were
found in the cervical cord of patients with RRMS71,74 and
primary progressive multiple sclerosis74 compared to con-
trols, which further decreased over 5 years follow-up.74
In contrast to MTR, MTsat has been evaluated in patients
with multiple sclerosis in a few studies, revealing its sensitiv-
ity to normal-appearing white/grey matter abnormalities75,76
and multiple sclerosis lesions.76,77 A proper comparison be-
tween the sensitivity of MTsat and MTR to multiple scler-
osis pathology has still to be performed, but there is
preliminary evidence that MTsat in the cervical spinal cord
better correlates with disability than MTR.78
Myelin maps provided by REMyDI showed increased
myelin loss in normal-appearing white matter of patients
with multiple sclerosis compared to controls, which corre-
lated with baseline cognitive and physical disability.56
Longitudinally, MWF correlated with follow-up physical dis-
ability, even after adjusting for baseline disability.56
Technology availability in the clinic
Up to now, MTR/MT sat, qT2, and MWF have not been
available for clinical use (Table 2). However, there are now
some sequences that provide qT2 and MWF maps in 3–6
min, a time that may be compatible with clinical proto-
cols.79–82 Similarly, for the cervical spinal cord, fast acquisi-
tions for MWF begin to be available.83
There are also several sequences available to perform MT
imaging, but none can provide the reconstruction of MTR
maps in a clinical setting. Interestingly, the comparison of
different myelin-sensitive methods (GRASE- and
mcDESPOT-MWF, qT1, and MTR) indicates that the type
of sequence needs to be chosen according to the purpose of
its application. For example, the GRASE sequence should be
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used when the greatest confidence is required for assessing
changes specific to myelin.39 If sensitivity to lesion and
normal-appearing white matter pathology is the priority,
then mcDESPOT-MWF and qT1 are the most sensitive
approaches.39
Although achieving reproducible MTR measurement has
traditionally been challenging, by carefully controlling the
sources of technical variability (protocols, type of coil for
MT saturation, and B1 inhomogeneities), it is feasible to ob-
tain inter-scanner MTR in healthy controls, the variability of
which lies within the mean inter-subject variability.84,85
Also, MTsat exhibits moderate variations [CV intra-scanner
7–12%; CV inter-scanner: 15.7% (55% if MT harmoniza-
tion is performed)].86
Intra-scanner reproducibility of MWF in white matter is
quite high (r = 0.95–0.99),81,82,87 and the same holds true in
small areas simulating multiple sclerosis lesions (r = 0.8962).
Slightly lower, but still very good, is the inter-scanner and
inter-vendor reproducibility for some myelin water imaging
sequences in white matter (r = 0.91, CV5 3%88) although
more studies are required to elucidate this aspect also for
other ‘clinically compatible’ MWI sequences.
An initial assessment of reproducibility of myelin maps as
provided by SyMRI, including REMyDI, showed moderate
reproducibility across vendors (rho = 0.89).76
In the spinal cord, measurement errors for MTR and
MTsat remain very large,89 and more data are required to
understand the intra- and inter-scanner reproducibility of
fast spinal MWF acquisitions.
Diffusion microstructure
Diffusion MRI probes CNS tissue integrity using metrics
derived from modelling signal changes associated with the
diffusion of water molecules in tissue, which can characterize
cellular compartments of brain tissue within multiple scler-
osis lesions, normal-appearing white matter, and normal-
appearing grey matter (Table 1 and Fig. 1).
Diffusion tensor imaging (DTI) is a technique widely avail-
able in clinical research and clinical practice. DTI-derived
metrics [fractional anisotropy (FA), radial/axial diffusivity
(RD/AD), and mean diffusivity (MD)/apparent diffusion co-
efficient (ADC)] have been used for many years to assess the
CNS tissue integrity in both regions of interest and along
specific white matter tracts.90–93 Beyond DTI, several math-
ematical models and computational approaches have
attempted to decode the information contained in diffusion-
weighted signals to retrieve specific features of tissue micro-
structure by: (i) modelling the tissue (e.g. tissue geometry
and water dispersion) and associated signals; or (ii) compu-
tationally exploring the magnetic resonance signal (e.g.
assessing signal behaviour with minimal or no underlying
geometrical assumptions). Some models have attempted to
separate different water compartments (extracellular, intra-
cellular, and other) within CNS tissue.94 These approaches
normally require diffusion acquisitions that are more com-
plex than the ones clinically used for DTI, encompassing
multiple b-values and sampling the signal in numerous direc-
tions. Extensive work comparing different diffusion-
weighted imaging models and their ability to explain
acquired data demonstrated that on average, and with the
methods tested, tissue models tend to explain diffusion-
weighted signal behaviour better than do signal models.95
The composite hindered and restricted model of diffusion
(CHARMED) separates the intra- and extracellular water
compartments and generates maps of the restricted water
fraction (FR), a proxy for axon density.96 The CHARMED
framework has been extended to account for different axon-
al diameters, providing the opportunity to map the distribu-
tion of axon diameters within the brain using AxCaliber97,98
or ActiveAx99 frameworks. Another method is diffusion kur-
tosis imaging (DKI), which aims to provide a more accurate
model of diffusion-weighted signal changes capable of cap-
turing non-Gaussian diffusion behaviour as a reflection of
tissue heterogeneity.100 Diffusion-based spectrum imaging
(DBSI) models the diffusion signal as a linear combination
of anisotropic diffusion tensors reflecting fibres, which are
predominantly axon fibres in white matter, and a spectrum
of isotropic diffusion tensors that encompass cells, oedema,
and CSF.101,102
Neurite orientation dispersion and density imaging
(NODDI) is a three-compartment tissue model providing
metrics to measure the intracellular volume fraction (ICVF)
or neurite density index (NDI) and the orientation dispersion
index (ODI), which describe intracellular diffusion in terms
of neurite density and the degree of fibre dispersion of neur-
itis, respectively.103 Soma and neurite density imaging
(SANDI) is another tissue-model aimed at further distin-
guishing the intracellular space by separately modelling the
intra-neurite and intra-soma spaces.104
Q-space imaging may be applied to study the microstruc-
tural changes in white matter by estimating the water
diffusion function, the probability density function (PDF),
also called mean apparent propagator (MAP)105 or ensemble
average propagator (EAP).106,107
Pathological evidence
Post-mortem studies showed that DTI-derived FA and MD
in normal-appearing white matter correlate to myelin con-
tent (r = –0.79 and r = 0.68, P5 0.001 for both) and to a
lesser degree axon count (r = –0.7 and r = 0.66, P5 0.001
for both).108 Also, in the cortex of non-neurological subjects
and patients with multiple sclerosis, FA values strongly relate
to axon density [b (95% CI) = 1.56 (0.69 to 2.44) and
b (95% CI) = 0.93 (0.45 to 1.42), P5 0.05 for both] but
not to myelin, glia, and total cell density.109 However, these
results should be taken with caution as the relationship
between DTI parameters and myelin/axon content decreases
in lesions and varies in regions of complex microstructure
(e.g. crossing fibres110–113).
Post-mortem validation of microstructural features derived
from biophysical diffusion models has been performed for
some models. However, very few of these models have been
evaluated in multiple sclerosis tissue specimens. AxCaliber
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showed a very high agreement between the estimated axon
diameter distribution in various nerve samples and axon
diameter histograms on histology images (r = 0.98 for optic
nerve and r = 0.86 for sciatic nerve97). ActiveAx maps of
axon diameter and density indices exhibited a similar distri-
bution pattern to those observed histopathologically in the
corpus callosum and corticospinal tract.99 NODDI ODI has
been reported to correspond well with histological measures
of neurite orientation dispersion in brain and spinal cord
(controls: r = 0.84; P5 0.001; multiple sclerosis: r = 0.60;
P = 0.001), whereas NODDI NDI showed good correlation
with myelin (r = 0.74; P5 0.001) and moderate correlation
with histology-derived neurofilament density measures (r =
0.56; P = 0.002).114,115 In post-mortem specimens of mul-
tiple sclerosis lesions in the spinal cord, lower NDI and
increased ODI were observed compared to non-lesion tis-
sue.114 Also, in the same specimens, NDI was reported to be
sensitive to myelin and axon count.114 As to DBSI, the study
of one biopsied tumefactive multiple sclerosis lesion showed
that DBSI-derived AD better detected axonal loss that
DTI116 but no correlation between DBSI parameters and
axonal density was reported.
Other emerging microstructural diffusion models still re-
quire histopathological validation in healthy controls and
multiple sclerosis brain specimens.
Assessment of multiple sclerosis impact and prognostic
value
Even though DTI measures provide only a coarse approxi-
mation of CNS tissue properties, they have been extensively
used in multiple sclerosis research studies. Increases in MD/
ADC have been reported up to 6 weeks before contrast
enhancement,117,118 and MD in enhancing lesions has been
shown to be much lower than in non-enhancing lesions.119
Increased MD in acute multiple sclerosis lesions also
appeared to predict risk of developing persistent black
holes.120 Furthermore, DTI measures along white matter
tracts showed a progressive increase in MD in patients with
no evidence of clinical or radiological disease-activity,121
and a decrease in RD as well as an increase in AD in pro-
gressive patients with multiple sclerosis.91 In addition, the
peak width of skeletonized MD appeared to be higher in
RRpatients with multiple sclerosis compared to controls.122
Recent DTI studies in the cervical spinal cord have reported
increased RD and reduced FA in RRMS with acute spinal
cord involvement, when compared with healthy controls,
and in SPMS, when compared with clinically stable
RRMS.123,124
DTI metrics in the brain can also predict disability
progression125 and cognition,126 especially in combination
with clinical variables.127 Likewise, RD in the optic nerve is
inversely related to visual acuity in patients with multiple
sclerosis128 and has been shown—together with FA—to cor-
relate with clinical disability in patients with spinal cord
lesions.124,129 Furthermore, baseline RD in the cervical
spinal cord over a 6-month period during an acute cord
relapse correlates with recovery at 6 months.130 Also, FA
and MD change over time in patients with multiple sclerosis,
but those measure do not seem to relate to changes in
disability.131
DKI measures (e.g. mean kurtosis) are affected in patients
with multiple sclerosis compared to controls132 and are
related to patient’s disability.133 DBSI-derived measures in
white matter lesions and in the corpus callosum distin-
guished clinical multiple sclerosis subtypes with moderate ac-
curacy134 and also different types of multiple sclerosis
lesions.135
The CHARMED-derived restricted water fraction is
decreased in early multiple sclerosis, both in lesions and in
normal-appearing white matter,136 and decreases over time
in lesions and normal-appearing white matter.137 NODDI
shows a lower neurite density (NDI) together with a higher
neurite orientation dispersion (ODI) in normal-appearing
white matter and in multiple sclerosis lesions compared with
healthy white matter, both in the brain137–139 and in the cer-
vical spinal cord.114,140,141 NODDI abnormalities are more
pronounced in patients with SPMS than RRMS.139
Additionally, NODDI measures better correlate with disabil-
ity and cognitive/motor function in patients with multiple
sclerosis than do standard DTI metrics.139
Last, q-space imaging (QSI) perpendicular diffusivity is
higher and parallel diffusivity lower in the cervical spinal
cord of progressive PPMS compared to healthy subjects,142
and those changes become more evident over time.143 Also,
an increase in cord QSI indices of perpendicular diffusivity is
associated with disability worsening over 3 years in
PPMS.143
Technology availability in the clinic
Currently, DTI protocols are available for most clinical
scanners and could be used in clinical practice, although
DTI measures are more often used for comparisons between
patient groups in research studies than for management of
individual patients. More studies are needed to better under-
stand the clinical validity of DTI-derived metrics for patients
with multiple sclerosis.110
Reproducibility of DTI metrics has been assessed in
numerous studies, which showed that FA has an intra-
scanner coefficient of variation 53% and MD 0–7%,
whereas the inter-scanner coefficient of variability for both
FA and MD is reported to be 45%.144–150 Nevertheless,
further studies should assess DTI reproducibility in multiple
sclerosis cohorts.
Microstructural models applied to multi-shell diffusion
data are far from being ready for clinical adoption, and only
few reproducibility studies have been performed. Among
those, some works reported an inter-vendor reproducibility
of NODDI ranging from 2.3% to 14% and an intra-scanner
reproducibility 44%.151,152 More works are required to
understand the potential clinical role of microstructural met-
rics and their reproducibility across scanners and vendors.
As for the spinal cord, a recent investigation of the repro-
ducibility of DTI-derived measures at C1–C6 between differ-
ent sites has shown the feasibility of multicentre spinal cord
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DTI, when sequence parameters are homogenized across
sites and vendors.153
Quantitative susceptibility mapping
Quantitative susceptibility mapping (QSM) encompasses
imaging methods by which the absolute concentrations of
iron, calcium, myelin, and other substances may be meas-
ured in tissues based on their changes in local magnetic sus-
ceptibility (Table 1). In particular, the magnetic susceptibility
is calculated from local frequency shifts in the MRI signal of
a gradient echo sequence (as obtained from the phase
images) through deconvolution with a dipole kernel. Several
methods have been proposed to solve this ill-posed inverse
problem.154 QSM maps can quantify paramagnetic trace ele-
ments, such as iron in ferritin, deoxygenated-heme in the
blood, and diamagnetic calcium. In addition, myelin155 and
the microstructural anisotropy of white matter156–159 can
also induce local shifts of the magnetic susceptibility because
of the diamagnetism of proteins and lipids.160 QSM also
provides an improved contrast-to-noise ratio for certain tis-
sues and structures compared with T2*-weighted magnitude
images. However, because of phase filtering, QSM does not
provide absolute susceptibility values, and, therefore, QSM
is computed in relationship to a reference region.161
Moreover, the magnetic susceptibility in white matter is a
tensor (i.e. it depends on fibre orientation with respect to the
main magnetic field, B0), which can make the interpretation
of susceptibility changes in white matter challenging.162
Pathological evidence
A post-mortem study before and after brain fixation at 7 T
showed that QSM is positively related to ferritin iron con-
tent (r = 0.76) and negatively related to myelin content (r =
–0.35), which indicates a paramagnetic effect of iron and a
diamagnetic effect of myelin on tissue magnetic susceptibil-
ity.163 In multiple sclerosis brain samples, QSM identifies
iron accumulation in microglia and macrophages surround-
ing chronic active and smoldering lesions164,165 as well as
active myelin digestion during lesion formation.166
Assessment of multiple sclerosis impact and
prognostic value
QSM reveals magnetic properties sensitive to iron and mye-
lin, and thus can capture specific characteristics of multiple
sclerosis lesions (Fig. 1). Longitudinal QSM measurements in
patients with multiple sclerosis have shown an initial large
rise in magnetic susceptibility occurring within weeks in ac-
tive lesions, and a subsequent increase that occurs for
months.167 The former has been attributed to myelin diges-
tion and the latter to the removal of the myelin debris within
macrophages and the release of iron.167 In addition, lesions
with higher susceptibility at the border and larger volume
maintained a high magnetic susceptibility value for a number
of years,167 a finding confirmed by susceptibility-weighted
imaging (SWI) at ultrahigh field.164 These lesions are particu-
larly interesting as they are thought to contain smouldering
inflammation and are associated with rapid clinical progres-
sion.168 Magnetic susceptibility values in the basal ganglia
were higher in patients with clinically isolated syndrome and
multiple sclerosis than in control subjects.154 Furthermore,
this increased iron deposition in the basal ganglia, measured
by QSM at 7 T, correlated with cognitive measures of inhibi-
tory control in patients with multiple sclerosis.169
Magnetic susceptibility values from QSM maps showed
promise in detecting enhancing lesions without the use of
gadolinium.167 Finally, QSM is also sensitive to the oxygen-
ation state of blood, thereby allowing calculation of the oxy-
gen extraction fraction. Thus, patients with multiple
sclerosis were found to exhibit lower oxygen extraction frac-
tion than controls, which is possibly related to mitochondrial
dysfunction.170
Technology availability in the clinic
It is relatively easy to collect data that may be used to recon-
struct QSM maps on clinical MRI scanners. In fact, many
clinical protocols are already applying 2D or 3D GRE (gra-
dient echo) sequences to obtain T2*-weighted or SWI, and
these protocols may also be used for QSM if phase images
are available. Currently, the main hurdle for the broad trans-
lation of QSM into clinics is that MRI vendors have yet to
implement the necessary algorithms on their commercial
scanners. In addition, offline reconstruction of QSM maps is
laborious and not easy to implement in routine clinical prac-
tice. Also, there is currently no consensus about which algo-
rithm is best for QSM reconstruction. Most current QSM
approaches suffer from over-smoothing and loss of conspi-
cuity of fine features, as the methods are primarily optimized
to minimize error metrics, not improve image quality.171
Brain QSM measurements performed by using the same
algorithm in different magnetic resonance scanners exhibit:
(i) excellent inter- and intra-scanner reproducibility for
healthy subjects (r = 0.99 and r = 0.98, respectively)172; (ii)
very high intra-scanner reproducibility for patients with mul-
tiple sclerosis (r = 0.97)172; and consistently high intra- and
inter-scanner reproducibility in phantoms with different
gadolinium concentrations.173
To date, QSM has not been developed for spinal cord
imaging.
Perfusion imaging
Blood perfusion in the brain can be assessed using a tracer in-
jection (e.g. gadolinium-based contrast agents) during the
MRI acquisition of: (i) a T2*-weighted dynamic susceptibility
contrast (DSC) sequence, which may provide relevant param-
eters in patients with multiple sclerosis such as: cerebral blood
flow, cerebral blood volume, and mean transit time; or (ii) a
T1-weighted dynamic contrast enhancement (DCE) sequence
able to measure the volume transfer constant Ktrans, which is
a measure of permeability between blood plasma and tissue
extravascular spaces and of plasma blood flow and capillary
surface area. Alternatively, arterial spin labelling (ASL), a
technique which does not require intravenous administration
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of gadolinium-based contrast agents, uses magnetically
labelled blood as the intrinsic contrast agent, most commonly
measuring cerebral blood flow and volume.
Pathological evidence
Chronic hypoperfusion induces mitochondrial dysfunction
leading to energetic failure and oxidative stress, which are
increasingly recognized as crucial factors associated with
axonal degeneration in multiple sclerosis.174 Furthermore,
generalized microstructural damage in normal-appearing
white matter could be associated with elevated levels of
endothelin-1, a vasospastic peptide.175
Assessment of multiple sclerosis impact and
prognostic value
Changes in local perfusion are known to precede the initial
blood–brain barrier breakdown and T2-weighted lesion ap-
pearance by several weeks.176 In general, lesions tend to de-
velop preferentially in hypoperfused brain areas,177 but the
relation of hypoperfusion to T2-weighted lesion load is con-
troversial.178–180 Generalized hypoperfusion in normal-
appearing white matter is correlated with microstructural
damage in the brain parenchyma.174 Brain perfusion is gener-
ally reduced in chronic disease phases,181,182 is correlated
with diffuse axon degeneration,174 and precedes atrophy de-
velopment.183 Gliosis also induces less metabolic demand and
results in decreased perfusion.176 Reductions in cerebral blood
volume and cerebral blood flow in multiple sclerosis are asso-
ciated with worsening of physical disability184 and have been
widely reported to correlate with disability and composite
functional scores.181,182,185–187 Correlations with the mean
transit time are still controversial, as this parameter is not
consistently altered in multiple sclerosis as it is in other condi-
tions such as stroke.185–187 A multitude of studies have con-
sistently described the correlation between cognitive decline
and reduced perfusion parameters,180,188–191 as well as with
fatigue in multiple sclerosis.188,190,192 Hypercapnic perfusion
experiments showed impaired dilatory capacity of cerebral
arterioles in multiple sclerosis in response to vasomotor
stimulations.193
Technology availability in the clinic
In general, perfusion data in multiple sclerosis may be ham-
pered by sensitivity to artefacts, dependency on haematocrit,
and the lack of absolute quantification, which may render dif-
ficult the interpretation and comparison of data acquired at
different time points or across scanners.194–196 Standardization
of protocols and analyses is currently under development.
Towards clinical application
and clinical decision support
with quantitative MRI
In theory, quantitative MRI techniques that measure accur-
ately and reproducibly a biologically specific signal
correlating with, or predictive of, clinical outcomes, are ideal
candidates for clinical applications. In practice, such techni-
ques do not exist yet (Tables 1 and 2). Among the currently
available quantitative MRI approaches, those achieving high
accuracy (which usually comes at the cost of reproducibility)
are extremely appealing for research investigating the under-
lying tissue changes; on the other end, those providing high
reproducibility, acceptable accuracy, and good correlation
with clinical measures, despite not comprehensively explain-
ing clinical function or disability, may be useful for the man-
agement of people with multiple sclerosis or in assessing
therapies for patients with multiple sclerosis.
Currently, quantitative MRI techniques lack some of the
development steps necessary to achieve clinical maturity
(Fig. 2). These include clinical availability of acquisition
methods and tools to reconstruct parametric maps; methods
to extract quantitative information from parametric maps;
and normative values and pathological cut-offs (Fig. 2).
Additionally, the clinical value of quantitative maps needs to
be compared with existing diagnostic and prognostic criteria
in the clinical setting. In this context, qT1 (e.g. MP2RAGE
and SyMRI) and, to some extent, myelin imaging (e.g.
SyMRI) appear to be the most technically advanced and
ready for use in studies aimed at providing methods to ex-
tract quantitative information, either through brain and spi-
nal cord atlases197–199 or comparison of single subjects to
large cohorts of healthy cohorts21 (Fig. 2). Although brain
myelin imaging may be ready for clinical adoption, we still
lack software solutions that can provide clinicians with valu-
able information related to the state of damage or repair of
the underlying tissue. QSM and diffusion-based methods
providing microstructural information warrant further
technological development, and their reproducibility must be
assessed in a multicentre setting. Finally, while perfusion
MRI may be considered to assess blood–brain barrier per-
meability and for monitoring disease progression, more stud-
ies are needed to provide evidence of its clinical value in
multiple sclerosis.
Another important consideration is whether specific quan-
titative MRI methods are better suited for the characteriza-
tion of specific multiple sclerosis disease subtypes,
assessment of disease progression, and evaluation of therapy
response. The data presented in this review suggest that, cur-
rently, T1 relaxometry and QSM may be most suitable for
multiple sclerosis stratification by contributing to the identi-
fication of lesions associated with more extensive tissue dam-
age and to the differentiation of acute versus chronic
inflammatory lesions. Myelin-sensitive quantitative MRI
techniques [MTR/MTsat, myelin water imaging (MWI), and
T2 relaxometry] and diffusion-microstructure MRI measure-
ments may be most appropriate for assessing clinical pro-
gression through the characterization of normal-appearing
tissue abnormalities, and may also be used to evaluate ther-
apy effects on specific CNS tissue components (e.g. myelin
and axons). As quantitative MRI methods become better
standardized, further studies will be required to define their
role in the management of patients with multiple sclerosis.
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Besides cerebral imaging, quantitative MRI (e.g. DTI,
MTR/MTsat, and MWI) also holds promise for imaging of
the spinal cord, but both additional software (for localiza-
tion, gating, and motion compensation) and hardware devel-
opment (e.g. multi-channel phased-array coils) are required
to pave the path towards application of spinal quantitative
MRI for multiple sclerosis management.
In summary, quantitative MRI has the potential to provide
information that can improve patient stratification, assess-
ment of therapy response, and evaluation of subclinical dis-
ease progression. Whether these techniques should be
embedded in clinical routines or selected for targeted imple-
mentations and studies within the clinical arena is still to be
determined. Future work should be targeted at improving
quantitative MRI clinical maturity through multicentre
collaborations.
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(Barcelona), M.A. Rocca (Milan, Co-Chair), and T. Yousry
(London).
References
1. Rovira A, Wattjes MP, Tintore M, et al. Evidence-based guide-
lines: MAGNIMS consensus guidelines on the use of MRI in mul-
tiple sclerosis-clinical implementation in the diagnostic process.
Nat Rev Neurol. 2015;11:471-482.
2. Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines:
MAGNIMS consensus guidelines on the use of MRI in multiple
sclerosis–establishing disease prognosis and monitoring patients.
Nat Rev Neurol. 2015;11:597-606.
3. Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on
magnetic resonance imaging in multiple sclerosis: Practical guide-
lines. Brain. 2019;142:1858-1875.
4. Pierpaoli C. Quantitative brain MRI. Top Magn Reson Imaging.
2010;21:63.
5. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M,
Lassmann H. Heterogeneity of multiple sclerosis lesions:
Implications for the pathogenesis of demyelination. Ann Neurol.
2000;47:707-717.
6. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS)
lesions: Pathology of the time frame of MS. Neuropathol Appl
Neurobiol. 2000;26:2-10.
7. Barnett MH, Prineas JW. Relapsing and remitting multiple scler-
osis: Pathology of the newly forming lesion. Ann Neurol. 2004;
55:458-468.
8. Luchicchi AK, Perna L, Frigerio I, ’t Hart BA, Stys PK, Schenk
GJ, Geurts JJG. Disturbed axon-myelin interaction in MS normal
appearing white matter. Stockholm, Sweden: ECTRIMS; 2019.
9. Dutta R, Chang A, Doud MK, et al. Demyelination causes synap-
tic alterations in hippocampi from multiple sclerosis patients.
Ann Neurol. 2011;69:445-454.
10. Helms G. Tissue properties from quantitative MRI. In: AW
Toga, ed. Brain mapping: An encyclopedic reference. Cambridge,
MA: Academic Press; Elsevier; 2015. 287-294.
11. Stuber C, Morawski M, Schafer A, et al. Myelin and iron concen-
tration in the human brain: A quantitative study of MRI contrast.
Neuroimage. 2014;93:95-106.
12. Seewann A, Kooi EJ, Roosendaal SD, Barkhof F, van der Valk P,
Geurts JJ. Translating pathology in multiple sclerosis: The com-
bination of postmortem imaging, histopathology and clinical
findings. Acta Neurol Scand. 2009;119:349-355.








niversity of Verona user on 11 M
ay 2021
13. Mottershead JP, Schmierer K, Clemence M, et al. High field MRI
correlates of myelin content and axonal density in multiple scler-
osis-a post-mortem study of the spinal cord. J Neurol. 2003;250:
1293-1301.
14. Jonkman LE, Soriano AL, Amor S, et al. Can MS lesion stages be
distinguished with MRI? A postmortem MRI and histopathology
study. J Neurol. 2015;262:1074-1080.
15. Brex PA, Parker GJ, Leary SM, et al. Lesion heterogeneity in mul-
tiple sclerosis: A study of the relations between appearances on
T1 weighted images, T1 relaxation times, and metabolite concen-
trations. J Neurol Neurosurg Psychiatry. 2000;68:627-632.
16. Kolb H. 7T MP2RAGE MRI for assessment of myelination status
in white matter lesions of multiple sclerosis. Stockholm, Sweden:
ECTRIMS; 2019.
17. Kober T, Granziera C, Ribes D, et al. MP2RAGE multiple scler-
osis magnetic resonance imaging at 3 T. Investigative Radiology.
2012;47:346-352.
18. Schmierer K, Parkes HG, So PW, et al. High field (9.4 Tesla)
magnetic resonance imaging of cortical grey matter lesions in
multiple sclerosis. Brain. 2010;133:858-867.
19. Beck ES, Sati P, Sethi V, et al. Improved visualization of cortical
lesions in multiple sclerosis using 7T MP2RAGE. AJNR Am J
Neuroradiol. 2018;39:459-466.
20. Fartaria MJ, O’Brien K, Sorega A, et al. An ultra-high field study
of cerebellar pathology in early relapsing-remitting multiple scler-
osis using MP2RAGE. Invest Radiol. 2017;52:265-273.
21. Bonnier G, Fischi-Gomez E, Roche A, et al. Personalized path-
ology maps to quantify diffuse and focal brain damage.
Neuroimage Clin. 2019;21:101607.
22. Vrenken H, Geurts JJ, Knol DL, et al. Normal-appearing white
matter changes vary with distance to lesions in multiple sclerosis.
AJNR Am J Neuroradiol. 2006;27:2005-2011.
23. Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping
in multiple sclerosis: Global changes of normal-appearing gray
and white matter. Radiology. 2006;240:811-820.
24. Thaler C, Faizy T, Sedlacik J, et al. T1-thresholds in black holes
increase clinical-radiological correlation in multiple sclerosis
patients. PLoS One. 2015;10:e0144693.
25. Thaler C, Faizy TD, Sedlacik J, et al. T1 recovery is predominant-
ly found in black holes and is associated with clinical improve-
ment in patients with multiple sclerosis. AJNR Am J
Neuroradiol. 2017;38:264-269.
26. Simioni S, Amaru F, Bonnier G, et al. MP2RAGE provides new
clinically-compatible correlates of mild cognitive deficits in relaps-
ing-remitting multiple sclerosis. J Neurol. 2014;261:1606-1613.
27. Ropele S, Langkammer C, Enzinger C, Fuchs S, Fazekas F.
Relaxation time mapping in multiple sclerosis. Expert Rev
Neurother. 2011;11:441-450.
28. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1
mapping: Basic techniques and clinical applications. JACC
Cardiovasc Imaging. 2016;9:67-81.
29. Stikov N, Boudreau M, Levesque IR, Tardif CL, Barral JK, Pike
GB. On the accuracy of T1 mapping: Searching for common
ground. Magn Reson Med. 2015;73:514-522.
30. Bane O, Hectors SJ, Wagner M, et al. Accuracy, repeatability,
and interplatform reproducibility of T1 quantification methods
used for DCE-MRI: Results from a multicenter phantom study.
Magn Reson Med. 2018;79:2564-2575.
31. Marques JP, Kober T, Krueger G, van der Zwaag W, Van de
Moortele PF, Gruetter R. MP2RAGE, a self bias-field corrected
sequence for improved segmentation and T1-mapping at high
field. Neuroimage. 2010;49:1271-1281.
32. Voelker MN, Kraff O, Brenner D, et al. The traveling heads:
Multicenter brain imaging at 7 Tesla. Magn Reson Mater Phys.
2016;29:399-415.
33. Yen Y-FK, Stupic KF, van der Kouwe A, Polimeni JR. T1 map-
ping of NIST Phantom at 7T. Honolulu, HI, USA: International
Society for Magnetic Resonance Imaging (ISMRM); 2017.
34. Warntjes JB, Leinhard OD, West J, Lundberg P. Rapid magnetic
resonance quantification on the brain: Optimization for clinical
usage. Magn Reson Med. 2008;60:320-329.
35. Hagiwara A, Warntjes M, Hori M, et al. SyMRI of the brain:
Rapid quantification of relaxation rates and proton density, with
synthetic MRI, automatic brain segmentation, and myelin meas-
urement. Invest Radiol. 2017;52:647-657.
36. Hagiwara A, Hori M, Kamagata K, et al. Myelin measurement:
Comparison between simultaneous tissue relaxometry, magnet-
ization transfer saturation index, and T1w/T2w ratio. Sci Rep.
2018;8:10554.
37. Rasoanandrianina H, Massire A, Taso M, et al. Regional T1
mapping of the whole cervical spinal cord using an optimized
MP2RAGE sequence. NMR Biomed. 2019;32:e4142.
38. Cortese R, Collorone S, Ciccarelli O, Toosy AT. Advances in
brain imaging in multiple sclerosis. Ther Adv Neurol Disord.
2019;12:175628641985972.
39. O’Muircheartaigh J, Vavasour I, Ljungberg E, et al.
Quantitative neuroimaging measures of myelin in the healthy
brain and in multiple sclerosis. Hum Brain Mapp. 2019;40:
2104-2116.
40. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M.
Magnetization transfer MRI metrics predict the accumulation of
disability 8 years later in patients with multiple sclerosis. Brain.
2006;129:2620-2627.
41. Rovaris M, Agosta F, Sormani MP, et al. Conventional and mag-
netization transfer MRI predictors of clinical multiple sclerosis
evolution: A medium-term follow-up study. Brain. 2003;126:
2323-2332.
42. Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of
opicinumab in patients with relapsing multiple sclerosis
(SYNERGY): A randomised, placebo-controlled, phase 2 trial.
Lancet Neurol. 2019;18:845-856.
43. Kremer D, Gottle P, Flores-Rivera J, Hartung HP, Kury P.
Remyelination in multiple sclerosis: From concept to clinical tri-
als. Curr Opin Neurol. 2019;32:378-384.
44. MacKay AL, Laule C. Magnetic resonance of myelin water: An
in vivo marker for myelin. Brain Plast. 2016;2:71-91.
45. Whittall KP, MacKay AL, Li DK. Are mono-exponential fits to a
few echoes sufficient to determine T2 relaxation for in vivo
human brain? Magn Reson Med. 1999;41:1255-1257.
46. Laule C, Leung E, Li DK, et al. Myelin water imaging in multiple
sclerosis: Quantitative correlations with histopathology. Mult
Scler. 2006;12:747-753.
47. Bonnier G, Roche A, Romascano D, et al. Advanced MRI unrav-
els the nature of tissue alterations in early multiple sclerosis. Ann
Clin Transl Neurol. 2014;1:423-432.
48. Warntjes M, Engstrom M, Tisell A, Lundberg P. Modeling the
presence of myelin and edema in the brain based on multi-para-
metric quantitative MRI. Front Neurol. 2016;7:16.
49. Bot JC, Blezer EL, Kamphorst W, et al. The spinal cord in mul-
tiple sclerosis: Relationship of high-spatial-resolution quantitative
MR imaging findings to histopathologic results. Radiology.
2004;233:531-540.
50. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR
imaging of brain iron: A postmortem validation study.
Radiology. 2010;257:455-462.
51. Laule C, Moore GRW. Myelin water imaging to detect demyelin-
ation and remyelination and its validation in pathology. Brain
Pathol. 2018;28:750-764.
52. Birkl C, Birkl-Toeglhofer AM, Endmayr V, et al. The influence of
brain iron on myelin water imaging. NeuroImage. 2019;199:
545-552.doi: 10.1016/j.neuroimage.2019.05.042.
53. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH.
Magnetization transfer ratio and myelin in postmortem multiple
sclerosis brain. Ann Neurol. 2004;56:407-415.
54. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal
loss in multiple sclerosis lesions: Magnetic resonance imaging








niversity of Verona user on 11 M
ay 2021
insights into substrates of disability. Ann Neurol. 1999;46:
747-754.
55. Moccia M, van de Pavert S, Eshaghi A, et al. Pathological corre-
lates of the magnetization transfer ratio in multiple sclerosis.
Neurology. 2020;95:e2965-e2976.
56. Ouellette R, Mangeat G, Polyak I, et al. Validation of rapid mag-
netic resonance myelin imaging in multiple sclerosis. Ann Neurol.
2020;87:710-724.
57. Neema M, Goldberg-Zimring D, Guss ZD, et al. 3 T MRI relax-
ometry detects T2 prolongation in the cerebral normal-appearing
white matter in multiple sclerosis. Neuroimage. 2009;46:633-641.
58. Romascano D, Meskaldji DE, Bonnier G, et al. Multicontrast
connectometry: a new tool to assess cerebellum alterations in
early relapsing-remitting multiple sclerosis. Hum Brain Mapp.
2015;36:1609-1619.
59. Whittall KP, MacKay AL, Li DK, Vavasour IM, Jones CK, Paty
DW. Normal-appearing white matter in multiple sclerosis has
heterogeneous, diffusely prolonged T(2). Magn Reson Med.
2002;47:403-408.
60. Gracien RM, Reitz SC, Hof SM, et al. Assessment of cortical
damage in early multiple sclerosis with quantitative T2 relaxome-
try. NMR Biomed. 2016;29:444-450.
61. Chatterjee S, Commowick O, Afacan O, Warfield SK, Barillot C.
Identification of Gadolinium contrast enhanced regions in MS
lesions using brain tissue microstructure information obtained
from diffusion and T2 relaxometry MRI. In: 21st International
Conference on Medical Image Computing and Computer
Assisted Intervention (MICCAI 2018). Grenade, Spain: Springer;
2018. 63-71.
62. Vargas WS, Monohan E, Pandya S, et al. Measuring longitudinal
myelin water fraction in new multiple sclerosis lesions.
Neuroimage Clin. 2015;9:369-375.
63. Yao Y, Nguyen TD, Pandya S, et al. Combining quantitative sus-
ceptibility mapping with automatic zero reference (QSM0) and
myelin water fraction imaging to quantify iron-related myelin
damage in chronic active MS lesions. AJNR Am J Neuroradiol.
2018;39:303-310.
64. Kolind S, Seddigh A, Combes A, et al. Brain and cord myelin
water imaging: A progressive multiple sclerosis biomarker.
Neuroimage Clin. 2015;9:574-580.
65. Laule C, Vavasour IM, Zhao Y, et al. Two-year study of cervical
cord volume and myelin water in primary progressive multiple
sclerosis. Mult Scler. 2010;16:670-677.
66. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G.
Magnetization transfer changes in the normal appearing white
matter precede the appearance of enhancing lesions in patients
with multiple sclerosis. Ann Neurol. 1998;43:809-814.
67. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in
multiple sclerosis: Magnetic resonance image appearance. Arch
Neurol. 2003;60:1073-1081.
68. Oh J, Ontaneda D, Azevedo C, et al. Imaging outcome measures
of neuroprotection and repair in MS: A consensus statement
from NAIMS. Neurology. 2019;92:519-533.
69. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al.
Patterns of lesion development in multiple sclerosis: Longitudinal
observations with T1-weighted spin-echo and magnetization
transfer MR. AJNR Am J Neuroradiol. 1998;19:675-683.
70. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL,
Canadian M. Magnetization transfer ratio evolution with demye-
lination and remyelination in multiple sclerosis lesions. Ann
Neurol. 2008;63:254-262.
71. Combes B, Kerbrat A, Ferre JC, et al. Focal and diffuse cervical
spinal cord damage in patients with early relapsing-remitting MS:
A multicentre magnetisation transfer ratio study. Mult Scler.
2019;25:1113-1123.
72. Kearney H, Rocca MA, Valsasina P, et al. Magnetic resonance
imaging correlates of physical disability in relapse onset multiple
sclerosis of long disease duration. Mult Scler. 2014;20:72-80.
73. Samson RS, Cardoso MJ, Muhlert N, et al. Investigation of outer
cortical magnetisation transfer ratio abnormalities in multiple
sclerosis clinical subgroups. Mult Scler. 2014;20:1322-1330.
74. Oh J, Chen M, Cybulsky K, et al. Five-year longitudinal changes
in quantitative spinal cord MRI in multiple sclerosis. Mult Scler.
2021;27:549-558.
75. Lommers E, Simon J, Reuter G, et al. Multiparameter MRI quan-
tification of microstructural tissue alterations in multiple sclerosis.
Neuroimage Clin. 2019;23:101879.
76. Saccenti L, Hagiwara A, Andica C, et al. Myelin measurement
using quantitative magnetic resonance imaging: A correlation
study comparing various imaging techniques in patients with
multiple sclerosis. Cells. 2020;9:393.
77. Bagnato F, Franco G, Ye F, et al. Selective inversion recovery
quantitative magnetization transfer imaging: Toward a 3 T clinical
application in multiple sclerosis. Mult Scler. 2020;26:457-467.
78. Lema A, Bishop C, Malik O, et al. A comparison of magnetiza-
tion transfer methods to assess brain and cervical cord micro-
structure in multiple sclerosis. J Neuroimaging. 2017;27:221-226.
79. Dvorak AV, Wiggermann V, Gilbert G, et al. Multi-spin echo T2
relaxation imaging with compressed sensing (METRICS) for
rapid myelin water imaging. Magn Reson Med. 2020;84:
1264-1279.
80. Hilbert T, Sumpf TJ, Weiland E, et al. Accelerated T2 mapping
combining parallel MRI and model-based reconstruction:
GRAPPATINI. J Magn Reson Imaging. 2018;48:359-368.
81. Nguyen TD, Deh K, Monohan E, et al. Feasibility and reproduci-
bility of whole brain myelin water mapping in 4 minutes using
fast acquisition with spiral trajectory and adiabatic T2prep
(FAST-T2) at 3T. Magn Reson Med. 2016;76:456-465.
82. Piredda GF, Hilbert T, Canales-Rodriguez EJ, et al. Fast and high-
resolution myelin water imaging: Accelerating multi-echo GRASE
with CAIPIRINHA. Magn Reson Med. 2021;85:209-222.
83. Dvorak AV, Ljungberg E, Vavasour IM, et al. Rapid myelin
water imaging for the assessment of cervical spinal cord myelin
damage. Neuroimage Clin. 2019;23:101896.
84. Barker GJ, Schreiber WG, Gass A, et al. A standardised method
for measuring magnetisation transfer ratio on MR imagers from
different manufacturers-the EuroMT sequence. Magma. 2005;18:
76-80.
85. Ropele S, Filippi M, Valsasina P, et al. Assessment and correction
of B1-induced errors in magnetization transfer ratio measure-
ments. Magn Reson Med. 2005;53:134-140.
86. Weiskopf N, Suckling J, Williams G, et al. Quantitative multi-
parameter mapping of R1, PD(), MT, and R2() at 3T: A multi-
center validation. Front Neurosci. 2013;7:95.
87. Meyers SM, Laule C, Vavasour IM, et al. Reproducibility of mye-
lin water fraction analysis: A comparison of region of interest
and voxel-based analysis methods. Magn Reson Imaging. 2009;
27:1096-1103.
88. Lee LE, Ljungberg E, Shin D, et al. Inter-vendor reproducibility
of myelin water imaging using a 3D gradient and spin echo se-
quence. Front Neurosci. 2018;12:854.
89. Levy S, Guertin MC, Khatibi A, et al. Test-retest reliability of
myelin imaging in the human spinal cord: Measurement errors
versus region- and aging-induced variations. PLoS One. 2018;13:
e0189944.
90. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectros-
copy and imaging. Biophys J. 1994;66:259-267.
91. Bodini B, Cercignani M, Toosy A, et al. A novel approach with
"skeletonised MTR" measures tract-specific microstructural
changes in early primary-progressive MS. Hum Brain Mapp.
2014;35:723-733.
92. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G.
Diffusion tensor MR imaging of the human brain. Radiology
1996;201:637-648.
93. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross
AH. Dysmyelination revealed through MRI as increased radial








niversity of Verona user on 11 M
ay 2021
(but unchanged axial) diffusion of water. Neuroimage. 2002;17:
1429-1436.
94. Novikov DS, Fieremans E, Jespersen SN, Kiselev VG.
Quantifying brain microstructure with diffusion MRI: Theory
and parameter estimation. NMR Biomed. 2019;32:e3998.
95. Ferizi U, Scherrer B, Schneider T, et al. Diffusion MRI micro-
structure models with in vivo human brain Connectome data:
Results from a multi-group comparison. NMR Biomed. 2017;30:
e3734.
96. Assaf Y, Freidlin RZ, Rohde GK, Basser PJ. New modeling and
experimental framework to characterize hindered and restricted
water diffusion in brain white matter. Magn Reson Med. 2004;
52:965-978.
97. Assaf Y, Blumenfeld-Katzir T, Yovel Y, Basser PJ. AxCaliber: A
method for measuring axon diameter distribution from diffusion
MRI. Magn Reson Med. 2008;59:1347-1354.
98. Barazany D, Basser PJ, Assaf Y. In vivo measurement of axon
diameter distribution in the corpus callosum of rat brain. Brain.
2009;132:1210-1220.
99. Alexander DC, Hubbard PL, Hall MG, et al. Orientationally in-
variant indices of axon diameter and density from diffusion MRI.
Neuroimage. 2010;52:1374-1389.
100. Wu EX, Cheung MM. MR diffusion kurtosis imaging for neural
tissue characterization. NMR Biomed. 2010;23:836-848.
101. Chiang CW, Wang Y, Sun P, et al. Quantifying white matter tract
diffusion parameters in the presence of increased extra-fiber cellu-
larity and vasogenic edema. Neuroimage. 2014;101:310-319.
102. Cross AH, Song SK. A new imaging modality to non-invasively
assess multiple sclerosis pathology. J Neuroimmunol. 2017;304:
81-85.
103. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC.
NODDI: Practical in vivo neurite orientation dispersion and
density imaging of the human brain. Neuroimage 2012;61:
1000-1016.
104. Palombo M, Ianus A, Guerreri M, et al. SANDI: A compartment-
based model for non-invasive apparent soma and neurite imaging
by diffusion MRI. Neuroimage. 2020;215:116835.
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